EPINEPHRINE INJECTION SOLUTION

국가: 캐나다

언어: 영어

출처: Health Canada

유효 성분:

EPINEPHRINE (EPINEPHRINE BITARTRATE)

제공처:

LABORATOIRE AGUETTANT

ATC 코드:

C01CA24

INN (국제 이름):

EPINEPHRINE

복용량:

1MG

약제 형태:

SOLUTION

구성:

EPINEPHRINE (EPINEPHRINE BITARTRATE) 1MG

관리 경로:

INTRAVENOUS

패키지 단위:

15G/50G

처방전 유형:

Ethical

치료 영역:

ALPHA-AND BETA-ADRENERGIC AGONISTS

제품 요약:

Active ingredient group (AIG) number: 0104871003; AHFS:

승인 상태:

APPROVED

승인 날짜:

2021-10-07

제품 특성 요약

PRESCRIBING INFORMATION
EPINEPHRINE INJECTION
0.1 mg / mL (Single-Use Syringes)
Sterile Solution
House standard
(Sympathomimetic)
Laboratoire Aguettant
1 rue Alexander Fleming
69007 Lyon
France
Imported to Canada by:
Aguettant Canada Inc.
1470 Peel Suite A-152, Montreal QC, H3A 1T1
Date of preparation:
07-10-2021
Control No.: 235107
2
NAME OF DRUG
EPINEPHRINE INJECTION
House Standard
0.1 mg / mL (Single-Use Syringes)
Sterile Solution
THERAPEUTIC CLASSIFICATION
Sympathomimetic
Epinephrine Injection is a parenteral adrenergic (sympathomimetic)
agent and cardiac stimulant.
ACTION AND CLINICAL PHARMACOLOGY
The actions of epinephrine resemble the effects of stimulation of
adrenergic nerves. It acts on both
alpha and beta receptor sites of sympathetic effector cells. Its most
prominent actions are on the beta
receptors of the heart, vascular and other smooth muscle. When given
by rapid intravenous injection,
it
produces
a
rapid
rise
in
blood
pressure,
mainly
systolic,
by
(1)
direct stimulation of cardiac
muscle which increases the strength of ventricular contraction, (2)
increasing the heart rate and (3)
constriction of the arterioles in the skin, mucosa and splanchnic
areas of the circulation.
When
given
by
slow
intravenous
injection,
epinephrine
usually
produces
only
a
moderate
rise in
systolic and a fall in diastolic pressure. Although some increase in
pulse pressure occurs, there is
usually
no
great
elevation
in
mean
blood
pressure.
Accordingly,
the
compensatory
reflex
mechanisms that come into play with a pronounced increase in blood
pressure do not antagonize the
direct cardiac actions of epinephrine as much as with catecholamines
that have a predominant action
on alpha receptors.
Total
peripheral
resistance
decreases by
action
of epinephrine
on
beta
receptors
of
the
skeletal
muscle vasculature and blood flow is thereby enhanced. Usually this
vasodilator effect of the drug
on
the
circulation
predominates
so
that
the
modest
rise
in
systolic
pressure
which
follows slow
injection
or
absorption
is
mainly
the
result
o